Esperite

Esperite Equity

Delisted

The The Equity of Esperite (ESP.AS) as of Nov 16, 2026 is 1.40 M EUR. In the previous year, The Equity was 6.94 M EUR — a change of -79.82% (lower).

Equity

1.40 MEUR

YoY

-79.82%

Last updated:

In 2017, Esperite's equity was 1.40 M EUR, a -79.82% increase from the 6.94 M EUR equity in the previous year.

The Esperite Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2014
21.28 M EUR
Jan 1, 2015
15.39 M EUR
Jan 1, 2016
6.94 M EUR
Jan 1, 2017
1.40 M EUR
The Esperite Equity history
YEAREquityYoY
1.40 MEUR-79.82%
6.94 MEUR-54.91%
15.39 MEUR-27.67%
21.28 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Esperite Stock analysis

What does Esperite do? Esperite NV is a company based in the Netherlands that specializes in the development, production, and marketing of stem cell and cell therapies. It focuses on creating groundbreaking therapies for the treatment of serious diseases and aims to market them worldwide. Its business model includes three main segments: Life Science, Consumer Healthcare, and Branding. The Life Science segment focuses on developing stem cell and cell therapies for the treatment of diseases such as autism, cancer, and degenerative disorders. The Consumer Healthcare segment offers products related to pregnancy and fertility assistance. The Branding segment involves the development and marketing of high-quality cosmetic products. Esperite's flagship product is CryoSave, a solution for the long-term preservation of stem cells from umbilical cord blood. Esperite is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Esperite's Equity

Esperite's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Esperite's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Esperite's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Esperite's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Esperite’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Esperite stock

The Equity of Esperite is 1.40 M EUR in 2017.

The Equity of Esperite changed from 6.94 M EUR to 1.40 M EUR, representing a -79.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Esperite since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Esperite historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Esperite

All Key Metrics — Esperite